EEG as a translational biomarker and outcome measure in fragile X syndrome
Sign Up to like & getrecommendations! Published in 2022 at "Translational Psychiatry"
DOI: 10.1038/s41398-022-01796-2
Abstract: Targeted treatments for fragile X syndrome (FXS) have frequently failed to show efficacy in clinical testing, despite success at the preclinical stages. This has highlighted the need for more effective translational outcome measures. EEG differences… read more here.
Keywords: fragile syndrome; translational biomarker; biomarker outcome; eeg translational ... See more keywords
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-003853
Abstract: Background There are no validated biomarkers that can aid clinicians in selecting who would best benefit from anticytotoxic T lymphocyte-associated antigen 4 monotherapy versus combination checkpoint blockade in patients with advanced melanoma who have progressive… read more here.
Keywords: advanced melanoma; translational biomarker; patients advanced; combination ... See more keywords